肝臓癌治療薬の世界市場2019-2023...市場調査レポートについてご紹介

【英文タイトル】Global Liver Cancer Drugs Market 2019-2023

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
• PART 04: PIPELINE ANALYSIS
• Pipeline analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Immunotherapy – Market size and forecast 2018-2023
• Targeted therapy – Market size and forecast 2018-2023
• Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Market trends
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bayer
• Bristol-Myers Squibb
• Eisai
• Merck
• Ono Pharmaceutical
PART 14: APPENDIX
• Research methodology
• List of abbreviations


Exhibit 01: Years in consideration
Exhibit 02: Global oncology therapeutics market
Exhibit 03: Segments of global oncology therapeutics market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Late-stage pipeline drugs for liver cancer
Exhibit 07: Market definition – Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ billions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition – Five forces 2018
Exhibit 19: Type – Market share 2018-2023 (%)
Exhibit 20: Comparison by type
Exhibit 21: Immunotherapy – Market size and forecast 2018-2023 ($ billions)
Exhibit 22: Immunotherapy – Year-over-year growth 2019-2023 (%)
Exhibit 23: Targeted therapy – Market size and forecast 2018-2023 ($ billions)
Exhibit 24: Targeted therapy – Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by type
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: Americas – Market size and forecast 2018-2023 ($ billions)
Exhibit 30: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 31: EMEA – Market size and forecast 2018-2023 ($ billions)
Exhibit 32: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 33: APAC – Market size and forecast 2018-2023 ($ billions)
Exhibit 34: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 35: Key leading countries
Exhibit 36: Market opportunity
Exhibit 37: Decision framework
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: Bayer – Vendor overview
Exhibit 45: Bayer – Business segments
Exhibit 46: Bayer – Organizational developments
Exhibit 47: Bayer – Geographic focus
Exhibit 48: Bayer – Segment focus
Exhibit 49: Bayer – Key offerings
Exhibit 50: Bristol-Myers Squibb – Vendor overview
Exhibit 51: Bristol-Myers Squibb – Business segments
Exhibit 52: Bristol-Myers Squibb – Organizational developments
Exhibit 53: Bristol-Myers Squibb – Geographic focus
Exhibit 54: Bristol-Myers Squibb – Key offerings
Exhibit 55: Eisai – Vendor overview
Exhibit 56: Eisai – Business segments
Exhibit 57: Eisai – Organizational developments
Exhibit 58: Eisai – Geographic focus
Exhibit 59: Eisai – Segment focus
Exhibit 60: Eisai – Key offerings
Exhibit 61: Merck – Vendor overview
Exhibit 62: Merck – Business segments
Exhibit 63: Merck – Organizational developments
Exhibit 64: Merck – Geographic focus
Exhibit 65: Merck – Segment focus
Exhibit 66: Merck – Key offerings
Exhibit 67: Ono Pharmaceutical – Vendor overview
Exhibit 68: Ono Pharmaceutical – Business segments
Exhibit 69: Ono Pharmaceutical – Organizational developments
Exhibit 70: Ono Pharmaceutical – Geographic focus
Exhibit 71: Ono Pharmaceutical – Key offerings
Exhibit 72: Validation techniques employed for market sizing
Exhibit 73: List of abbreviations



【レポート販売概要】

■ タイトル:肝臓癌治療薬の世界市場2019-2023
■ 英文:Global Liver Cancer Drugs Market 2019-2023
■ 発行日:2019年1月9日
■ 調査会社:Technavio
■ 商品コード:IRTNTR30608
■ 調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。